Health & Fitness
Health and Fitness
Health and Fitness
Mon, February 28, 2011Sun, February 27, 2011Fri, February 25, 2011Thu, February 24, 2011Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011PROTECT II Study Results Accepted for Presentation at 2011 ACC Show During Late Breaking Sessions
Published in Health and Fitness on Tuesday, February 22nd 2011 at 5:05 GMT by Market Wire
DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed Inc ]. (NASDAQ: ABMD), a leading provider of [ breakthrough heart support technologies ], today announced that the PROTECT II results have been accepted to be presented by William Oa™Neill, M.D., University of Miami, during the late-breaking clinical trials session at the American College of Cardiology (ACC) 2011 show.
The presentation will include data from approximately all 430 patients enrolled in the PROTECT II study, which includes the patients enrolled as of the interim analysis as well as the additional 125 patients enrolled after the initiation of the interim analysis.
The PROTECT II presentation is scheduled for Sunday, April 3 at 12:30 p.m. in Room 257 at the Ernest N. Morial Convention Center, New Orleans.
PROTECT II was a prospective multicenter randomized clinical trial of Impella versus the intra-aortic balloon pump for hemodynamic support during high risk percutaneous coronary intervention (PCI).
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
